Drug Pricing Probes Continue
Over the past year, pharmaceutical drug prices have received increased scrutiny from industry stakeholders, politicians and regulators. Emerging cancer treatments, Hepatitis C and blood pressure drugs have come under particular fire. After catching the attention of Democratic congressmen, United States (US) Attorneys from Manhattan and Boston subpoenaed Valeant Pharmaceuticals International.
The investigation will look into the company’s provision of financial aid to out-of-pocket payers as well as its drug pricing. Specifically, Valeant’s heart drugs, Nitropress and Isuprel, will be under inquiry. The move sends a message to other pharmaceutical providers who engage in dramatic and rapid price-increases. It also signals federal regulators and prosecutors’ commitment to the issue.